Skip to Content
Søg Menu

EHA 2024 I The European Hematology Association

EHA 2024

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

  • / BestPractice Nordic

Daniel Kristensen

Tillæg af andengenerations-FLT3-inhibitor til intensiv kemoterapi og konsolidering hos voksne med AML

/ Daniel Kristensen
EHA22AML Play the Video

Hematology • Meet the Experts

Get access

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
EHA24CLL

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
EHA24AML

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Anne Stidsholt Roug

Opdateringer fra EHA: Nye behandlingsmuligheder for AML og APL

/ Anne Stidsholt Roug
EHA24 Play the Video
Tarec Christoffer El-galaly

Opsigtvækkende fremskridt på EHA for behandling af lymfom

/ Tarec Christoffer El-Galaly
EHA24Lymfom Play the Video
Hent flere

Mest sete

MEDtalks

The Missing Link of Light Chain Smoldering Multiple Myeloma

/ Hæmatologi / Sigrun Thorsteinsdottir

LBA: Acalabrutinib plus Bendamustine and Rituximab Show Significant Improvement in PFS for Elderly Patients with Mantle Cell Lymphoma

/ Hæmatologi / Michael Wang

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

/ Hæmatologi / Maria Eugenia Chollet

Artikler

EHA24: LBA – Potential Frontline Treatment for Elderly Patients with Untreated Mantle Cell Lymphoma

/ Hæmatologi / Isabella Rosa Staffe

EHA24: New Treatment Regimen Marks a Breakthrough for Patients with Multiple Myeloma

/ Hæmatologi / Isabella Rosa Staffe

EHA24: Professor John Gribben Awarded Prestigious EHA José Carreras Award 

/ Hæmatologi / Isabella Rosa Staffe
Hanne Norseth

Vaccinating Against Mutated RAS in Multiple Myeloma

/ Hanne Norseth
EHA24Myelomatose Play the Video
Sergio Martinez Høyer

An Excellent Target with a Wide Therapeutic Window in del(5q) Myeloid Malignancies

/ Sergio Martinez Høyer
EHA24 Play the Video
Frida Bugge Askeland

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

/ Frida Bugge Askeland
EHA24Myelomatose Play the Video
Sigrid S. Skånland

From Genomic Precision Medicine to Functional Precision Medicine in Hematology

/ Sigrid S. Skånland
EHA24 Play the Video
Henrik Hjorth-Hansen

Management of CML in Adults: 2024 ELN Recommendations

/ Henrik Hjorth-Hansen
EHA24 Play the Video
Rasmus Rask Kragh Jørgensen

Development of Prediction Models for Survival among Hodgkin Lymphoma Patients

/ Rasmus Rask Kragh Jørgensen
EHA24Hodgkins lymfom Play the Video
Ângela Mesquita

Better Predictor of Treatment Efficacy of Myelodysplastic Syndromes

/ Ângela Sofia Gerós Mesquita
EHA24 Play the Video
Jelena Jelicic

More Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Can Participate in Clinical Studies

/ Jelena Jelicic
EHA24Lymfom Play the Video
Elin Forsgren

Ibrutinib, Lenalidomide, and Rituximab in Relapsed Mantle Cell Lymphoma

/ Elin Forsgren
EHA24Myelomatose Play the Video
Ari Melnick

Presidential Symposium: Unmet Needs in the Lymphoma Field

/ Ari M. Melnick
EHA24Lymfom Play the Video
Bruno Paiva

Presidential Symposium: Innovative Tools for Disease Monitoring in Multiple Myeloma

/ Bruno Paiva
EHA24Myelomatose Play the Video
Agoston Gyula Szabo

Dansk, investigator-initieret studie af lavdosis VEN-DEX hos patienter med RRMM og t(11;14) opnår en ORR på 50%

/ Agoston Gyula Szabo
EHA24Myelomatose Play the Video
Hent flere

EHA 2023

Carsten Niemann

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

/ Carsten Utoft Niemann
EHA23CLL Play the Video

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ BestPractice Nordic
EHA22Lymfom

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ BestPractice Nordic
EHA22AML
Anna Sureda Balari

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

/ Anna Sureda Balari
EHA23Lymfom Play the Video
Mark Levis

Gilteritinib for Patients with Newly Diagnosed AML

/ Mark Levis
EHA23Ernæring Play the Video
Arnon Kater

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Arnon Kater
EHA23CLL Play the Video
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Evangelos Terpos
EHA23Myelomatose Play the Video
Ryan Jacobs

News from EHA23 – A Promising Treatment Option for Follicular Lymphoma

/ Ryan Jacobs
EHA23Lymfom Play the Video
Barbara Eichhorst

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

/ Barbara Eichhorst
EHA23CLL Play the Video
Eva Futtrup Maksten

Risk of Dementia in Older Patients Treated with Chemotherapy for Lymphoma

/ Eva Futtrup Maksten
EHA23LymfomDemens Play the Video

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Evangelos Terpos / Jan Andreasen
EHA23Myelomatose
Alan Z. Skarbnik

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

/ Alan Z. Skarbnik
EHA23CLL Play the Video
Hent flere

Højdepunkter fra EHA webinar 2022

Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
B-celle lymfomLymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

MEDtalks fra EHA 2022

AML

Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

/ Hæmatologi / Gunnar Juliusson

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

/ Hæmatologi / Hanna Duàn

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Hæmatologi / Gunnar Juliusson

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Hæmatologi / Nikolaj Juul Nitschke

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Hæmatologi / Jad Othman
Se oversigt

CLL

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Hæmatologi / Ingrid Glimelius

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

/ Hæmatologi / Paolo Ghia

Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL

/ Hæmatologi / Jennifer R. Brown

Acalabrutinib Shows Promise for Elderly CLL Patients

/ Hæmatologi / Florian Simon

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Hæmatologi / Paolo Ghia
Se oversigt

Lymfom

Machine learning kan reducere unødvendige indlæggelser af kræftpatienter

/ Hæmatologi / Alexander Fuglkjær

Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024

/ Hæmatologi / Ingrid Glimelius

High Mortality Rate for Patients with Mantle Cell Lymphoma with a Second Primary Malignancy

/ Hæmatologi / Ingrid Glimelius

The Majority of Patients with Mantle Cell Lymphoma Probably Don’t Need Auto-Transplant in the Current Treatment Era

/ Hæmatologi / Timothy S. Fenske

There Is Definitely A Need for Novel Treatments for Elderly Patients with Mantle Cell Lymphoma

/ Hæmatologi / Mats Jerkeman
Se oversigt

Myelomatose

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Hæmatologi / Muhammad Kashif

Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

/ Hæmatologi / Meletios A. Dimopoulos

Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma

/ Hæmatologi / Frida Bugge Askeland

ASH 2024 Highlights: Early Smouldering Myeloma Treatment and Breakthrough Therapies in Multiple Myeloma Take Center Stage

/ Hæmatologi / Fredrik Schjesvold

Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing Frequency in Refractory Multiple Myeloma

/ Hæmatologi / Alexander Lesokhin
Se oversigt

Abstracts fra EHA 2022

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

/ Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

/ Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

/ Hæmatologi / BestPractice Nordic

Phase 2 study update: Epcoritamab demonstrates clinically meaningful and compelling efficacy in the treatment of R/R large B-cell lymphoma 

/ Hæmatologi / BestPractice Nordic

Phase 2 study update: Epcoritamab demonstrates clinically meaningful and compelling efficacy in the treatment of R/R large B-cell lymphoma 

  • / BestPractice Nordic

Se highlights EHA webinar 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
B-celle lymfomLymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Mere fra EHA 2022

Agoston Gyula Szabo

Værdien af højdosisbehandling som tillæg til Rvd induktion og konsolidering ved myelomatose

/ Agoston Gyula Szabo
EHA22Myelomatose Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Paolo Strati

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

/ Paolo Strati
EHA22Lymfom Play the Video

Mere fra EHA 2021

Kirsten Grønbæk

Hvad har GDPR betydet for den nordiske forskningsscene? Vigtigste take-aways fra EHA med Kirsten Grønbæk

/ clara
EHA22 Play the Video
Othman Al-sawaf

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

/ Othman Al-Sawaf
EHA22CLL Play the Video
Daniel Kristensen

Nyt landsdækkende studie stiller spørgsmålstegn ved betydningen af dosisreduktion hos overvægtige AML-patienter

/ Daniel Kristensen
EHA22AML Play the Video
Jean-Marie Michot

Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma

/ Jean-Marie Michot
EHA22Lymfom Play the Video
Paul Richardson

A new randomized study suggests an improved depth of response and PFS for patients relapsing on Lenalidomide

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Arnon Kater

The main clinical message from the Five-Year Analysis of Murano Study

/ Arnon P. Kater
EHA22CLL Play the Video
Læs mere
Paul Richardson

Longer PFS and higher ORR for frailty patients with R/R Multiple Myeloma treated with PVd than Vd

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Jakob Nordberg Nørgaard

A new study shows that PTCD and MRD are complementary and necessary for doing a whole assessment on patient-response for myeloma patients

/ Jakob Nordberg Nørgaard
EHA22Myelomatose Play the Video
Paul Richardson

Treatment with RVD + stem cell transplant achieved higher PFS vs RV alone In patients with newly diagnosed multiple myeloma

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Back to top